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A short review on pharmacokinetics-pharmacodynamics (PK-PD) presented below aims to show the evolution
of some concepts and ideas in this field. Some of them are developed in more detail in the papers of this issue.
The key question for a practical application of PK-PD models is the ability to estimate the model parameters
using patients data. In [1] a novel approach to an accurate quantification of the uncertainty in parameter estimates
attributed to inter-individual variability is proposed. The analyzed PK-PD model is formulated as a compartmental
ODE system. The methodology of recognizing and capturing the uncertainty in predicted quantities of interest
due to inter-individual variability when the individual is not available for repeated measurements may prove to
be invaluable in the risk assessment of future experiments and drug applications. Anticancer molecular PK-PD
in a cell population dynamics model with drug delivery optimisation is discussed in [2]. The works [3] and [4]
deal with various aspects of hemostasis modelling, and [5] with metabolic aspects in a whole-body setting. These
studies represent the diversity of aspects of PK-PD modelling nowadays: theoretical about parameter estimation in
general versus applied to medical questions in particular, localised cell population versus whole-body settings, cell
population and whole-body versus patient population settings.
1. “Spatial dimension” of PK-PD problems in immunology
The classical modelling approach in PK-PD is based on mathematical models representing a compartmental view
of the organism [6]. The models consider organs and cells as compartments in which the concentration of a drug
is spatially uniform or homogeneous. However, recent clinical and experimental studies of infections such as
human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) clearly indicate that the view has
to be extended to consider a genuine spatial dimension of the tissues and organs in which the infection and drug
distribution processes take place.
One of the first evidences of the key role of spatial distribution of drugs in the efficacy of antiretroviral (ART)
HIV treatment was presented in [7]. It was shown that HIV continues to replicate in lymphatic tissues of some in-
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dividuals under taking ART regimens considered fully suppressive, based on undetectable viral loads in peripheral
blood. One mechanism proposed to explain the persistent replication of HIV in lymphatic tissues was lower con-
centrations of the ART drugs in those tissues compared with peripheral blood. Overall, a clear association between
low drug concentrations in tissues and persistent viral replication was documented. The evidence has been further
corroborated in recent studies of the persistent productive HIV infection during therapy [8] and SIV infections in
elite controllers [9]. The existence of the drug-free zones in lymphoid tissues is broadly discussed in [10]. It is a
remarkable finding that multiple drug concentrations in lymph nodes can be about 100-times lower than those in
blood for the same patient [7].
To analyse the novel aspects of the drug dynamics and effect in organs spatially extended models of drug
transport in tissues are needed. For example, the drug concentration field can be studied using the reaction-diffusion
equation:
−div(D∇c(x))+αc(x) =
M
∑
k=1
ρδ (x− xk), (1.1)
where D is a tensor diffusion coefficient, D = D(i) in domains Ωi, i = 1, ...,N, specifying various structures of
the organs under investigation. The equation is understood in a weak sense. Although the above model is rather
simple, it can be used in conjunction with the anatomical description of the tissue structure to provide novel insights
into the spatial patterns of drug distribution in complex organ environments. Instructive example is provided by
studies of type I interferon (IFN) distribution in lymph nodes (LNs) [11, 12]. The structural organisation of LNs
is quite elaborate [13] and a paradigmatic view gives a simplified but still a representative geometry of the LN.
The 3D geometry of a paradigmatic LN approximated with a tetrahedral mesh is shown in Figure 1, left. The
elements considered include subcapsular sinus (SCS), trabecular sinuses, B-cell follicles,T cell zone, conduits.
This geometry requires a multiple length scale resolution for the representation of the conduits and other major
domains. The above reaction-diffusion partial differential equation governing the interferon dynamics was used
to analyse the steady-state distribution of IFN across the subdomains of the 3D lymph node. The LN domain Ω
consists of subdomains represesnting SCS Ω1, trabecular sinuses Ω2, conduit “network” Ω3, B cell follicle Ω4,
T cell zone Ω5. Obviously, the penetration of the cytokine to various parts of the LN is governed by the relative
balance of convection, diffusion and degradation/absorption of the IFN molecules. Under these settings, M is the
number of cell producing IFN, xk denotes the cell location, ρ is the production rate, α the degradation/absorbtion
rate of IFN. There is a non-homogeneity in diffusion coefficients D(1,2,3) = D∗, D(4) = 0.1D∗, D(5) = 0.01D∗ as
suggested by experimentally observed differences of small molecular tracers distribution in LN domains [14]. The
regions of LNs that contain T lymphocytes (the cortical and para-cortical zones or the Ω5 region) are characterised
by weak molecular diffusion, which is associated with poor hydraulic conductivity [14]. Calibrating the model
parameters using the estimates from [15,16] D∗ = dI,d = 0.16 mm2/hr, ρ = 4.4 ·10−4pg/hr, α = 0.012/hr allows
one to examine the extent of non-homogeneity of the IFN field in LN as shown in Figure 1, centre. The numerical
solution for the model predicts that a substantial variation of IFN concentration takes place within the LN, i.e.
by two orders of magnitude. Therefore the compartmentalisation of the cytokine can occur due to the diffusion
process. The conclusion is robust with respect to variations in geometrical structure of LN and justified variations
in the model parameter values. Type I interferon is generally considered as an antiviral drug for HIV infection.
In a broader context, it can be hypothesised that when the drug distributions is concerned the morphology and
biophysical properties of secondary lymphoid organs can lead to the formation of poorly protected areas. In these
areas, localization of the cells infected by viruses, such as CD4+ T lymphocytes or macrophages in the case of
HIV infection provides the conditions for the continuation of active infectious processes.
The effect of spatial compartmentalisation of this important cytokine in lymphoid tissue is predicted based on
embedding a reaction-diffusion model into a spatial 3D context of the LN and some basic information about the
hydraulic conductivity taken into account. Deeper insights into the spatial patterns of cytokine and drug penetration
into LN will require a finer approximation of the LN structures, e.g., such as the conduit network and the blood
microvascular system as well as studies of the molecular transport in domains densely packed with cells. Figure
1, right shows a 3D model of the LN with geometrically and topologically consistent representation of fibroblastic
reticular cell network. Some elements necessary to move in this direction has already been elaborated in recent
studies of fluid flow through LNs [17–20].
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FIGURE 1. Spatial organisation of lymph node (LN). Left: Finite-element based approxima-
tion of major structural elements of a paradigmatic LN. Centre: 3D reaction-diffusion model
predictions of the spatial distribution of type I interferon in LN. Color bar reflects the relative
concentration of the molecules. Right: Geometric model of LN with anatomically consistent
representation of the B-cell follicles and Fibroblastic Reticular Cell network.
2. Non-spatial models in oncology
Representing healthy and cancer proliferating cell populations, the targets of anticancer drugs, may involve space,
but most often the spatial structure of the cell populations is not known. Tumours are far from presenting them-
selves as spatially well-organised tissues; furthermore anticancer drugs act on molecular or functional targets in
cell populations, that are by nature highly heterogeneous in physiology as well in pathology. Space is thus not
necessarily relevant to describe their action, whose result is seen on cell population numbers or growth rates. Much
more relevant than space-structured models are physiologically structured models, that are amenable to account
for the relevant biological variability (=heterogeneity) of the cell population under study.
In this special issue, an age-structured transport model of the cell division cycle in healthy and cancer cell
populations is presented, following previous ones [21–24]. Its originality is that it is coupled with an ODE model
for the PK-PD of the two main drugs used in colorectal cancer: 5-fluorouracil and oxaliplatin. It has been originally
designed in the framework of chronotherapeutics (chrono-PK-PD) [25], but it can also be used outside of this
framework, provided that the time differences in gating at the cell cycle checkpoints between healthy and cancer
cell populations are preserved.
Given such fundamental differences, one can, as shown in the article of the present issue, design optimised
strategies for the delivery of anticancer drugs. The optimisation method proposed operates under the constraint
of preserving the healthy cell population. Another crucial aspect of theoretical therapeutic optimisation consists in
avoiding the emergence of resistant cell subpopulations, which is the other major pitfall of therapeutics in oncology.
It is only alluded at in this article, but it is studied in detail in [26, 27]. In the models used, cell populations are
structured in a phenotype representing the expression of drug resistance in the cells. They are basically non-
spatial, but space can be introduced as complementary structure variable when it is relevant to the description of
the heterogeneity under study, for instance if the tumour is assumed to be spheroid-shaped [27]. Then PK-PD ODE
models for the drug considered (a cytotoxic and a cytostatic) could be coupled to the phenotype-structured models
as it has been done in age-structured models of the cell cycle, but this remains to be done.
3. PK-PD and systems pharmacology in blood clotting pathologies
Developing mathematical models of blood coagulation is essential in understanding the pathogenesis of blood
clotting abnormalities such as thrombosis and hemophilia. Usually, the developed models are firstly built in order
to describe the dynamics of healthy blood coagulation. However, it is sufficient to change some parameters asso-
ciated with a coagulation disorder to describe pathological blood coagulation. The ultimate goal of these models
is to study the action of treatments on the coagulation process. Despite the wide range of mathematical methods
used in the development of PK-PD hemostasis models, the modellers are faced with numerous challenges due to
the complexity of the blood clotting system. Below, we present a state of the art of the approaches used in the
mathematical modelling of blood clotting disorders and their treatment.
Venous thrombosis is a blood clotting disorder characterized by the formation of excessive blood clots within a
vein resulting in the perturbation of blood flow. Warfarin and heparin are two anticoagulant drugs that are usually
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prescribed to prevent venous thrombosis [28]. In a recent model [29], the effect of warfarin on clot growth in flow
was studied. Warfarin is an anti-vitamin K drug which downregulates the synthesis of some clotting factors in the
liver. Its action is monitored by an in vitro assay called INR (international normalized ratio) which is based on
the necessary time for prothrombin conversion into thrombin. In order to prevent thrombosis, the INR should be
maintained between 2.0 and 3.0 during warfarin treatment. The authors used previously developed models for both
in vivo clot formation and in vitro PT and INR assays, and then compared the action of warfarin on individual
patients under these two conditions. They conducted numerical simulation describing clot growth during warfarin
treatment under various flow conditions. They concluded that the in vitro assays do not represent a reliable tool for
monitoring warfarin treatment due to the absence of blood flow in in vitro tests. This explains the persistence of
thrombosis for some patients even when their INR is in the targeted range.
In addition to warfarin, heparin is one of the commonly used venous thrombosis treatments. Heparin upregulates
the activity of antithrombin which reduces blood coagulability. In a recent work [30], Dydek and Chaikof equipped
a previously developed model for in situ clot growth with the action of heparin. The resulting model is detailed and
focuses on the spatio-temporal dynamics of clot growth during heparin treatment. The authors evaluated the effects
of different doses and types of heparin under venous and arterial flows and included the effect of circulating tissue
factor. In the future, this work can be combined with pharmacokinetics models of heparin treatments to assess the
efficacy and safety of various protocols.
A comprehensive model which encompasses both the PK-PD and the in vitro assays aspects of venous throm-
bosis was developed using systems pharmacology [31]. It uses ODEs to describe the concentrations of drugs,
proteins, and clotting factors in different time scales which affect each other. In this work, the authors compared
the results of different in vitro tests and clotting times such as PT and aPTT during anticoagulant treatment. They
studied the action of different drugs such as warfarin and heparin and simulated the pathogenesis of blood clotting
disorders such as thrombosis, hemophilia A and B. To the best of our knowledge, this is one of the few complex
models that were validated by experimental data in the literature. The model can serve as an in silico predicting
tool in drug development and clinical trials.
Although most of the PK-PD models of thrombosis study the action of warfarin and heparin, some of the
recent works are devoted to the action of new oral anticoagulants such as rivaroxaban. It is a direct factor Xa
inhibitor which is commonly used to prevent strokes and thrombo-embolic events in adult patients. An important
PK-PD model which assesses the efficacy and safety rivaroxaban treatments was developed by Burghaus et al.
[32]. This work is of practical interest because it is based on previously validated models [33, 34]. Furthermore,
it encompasses both the extrinsic and intrinsic pathways as well as the effects of blood flow on clot growth. All
of these factors make the model appropriate for clinical studies. Recently, the model was used in order to study
the optimal dosing schedule for switching from warfarin to rivaroxaban treatment (Burghaus et al. 2014). Another
systems pharmacology model of rivaroxaban action was developed by Zhou et al. [36]. It contains one of the most
complete descriptions of the blood coagulation cascade and accurately predicts clotting times during anticoagulant
treatment. Direct thrombin inhibitors are another class of new oral anticoagulant drugs which are used in the
prevention of thromboembolic events. Dabigatran etexilate is one of the commonly used direct thrombin inhibitors
as it can replace warfarin but does not require monitoring by the INR test. The only in vitro assay which can
potentially assess the efficacy and safety of such treatments is the thrombin generation test. In a recent study [37],
the authors used a calibrated version of this test to assess the efficacy of dabigatran. Although the study does not
directly provide a mathematical model which can be used in in silico dabigatran treatments assessment, it presents
valuable experimental data which can help the future developments of PK-PD models describing the action of
dabigatran on the coagulation process.
There are many other systems pharmacology models which describe blood coagulation pathologies and the
action of treatments ([38–42]). While most of these models are more appropriate for an accurate multi-scale de-
scription of the coagulation process during treatment, they are usually built in complex and sophisticated ways
that incorporate many details. As a result, it becomes difficult to interpret the obtained results and to derive simple
relations between the parameters of interest. To encourage the use of multi-scale models in clinical studies, Gulati
et al. showed how to reduce a 62-state model to 5-state model [39]. They also derived mechanistic relationships
between coagulation parameters that agree with experimental data.
Developing PK-PD models of blood coagulation pathologies requires an appropriate characterization of in-
dividual patientsṕrofiles. Brummel-Ziedins [43] addressed this point by developing and validating computational
approaches which capture the dynamics of thrombin generation in individual patients depending on plasma compo-
sition. Such approaches can be used in identifying thrombosis risk during anticoagulant treatments. Other models
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study the hemostatic response in individuals with pre-existing health conditions associated with clotting disorders
including rheumatoid arthritis [44], cancer [45], and deep venous thrombosis [46].
PK-PD models of thrombosis and other blood coagulation disorders represent a promising tool that can poten-
tially predict individual haemostatic responses. However, for these models to be incorporated in clinical studies,
it is crucial to confront them with in vitro and in vivo blood clotting experimental data. Ultimately, we can expect
that accurate computer models of blood coagulation will replace in vitro diagnostic assays. Until then, a significant
effort should be made in order to develop more accurate and experimentally validated models that capture all the
pathophysiological aspects of blood coagulation.
4. Future developments
4.1. Whole-body and multi-scale modelling
The development of patient-specific drug therapies requires high-resolution mathematical models for assimilating
of the vast amount of data including -omics, sequencing, flow cytometry, imaging, immune profiling characterizing
the organism response to drug intervention at various levels of resolution. Therapies of some complex pathologies
also include adoptive immune cell transfer in addition to drug injections. This combination of therapeutic agents of
different nature call for the models considering the spatial distribution of target cells (e.g., CD4 T cells in follicles
in HIV infection) and the migration of immune cells in various parts of the LN (e.g., CTL destroying infected
cells). Overall, a shift from a compartmental consideration of the PK-PD processes to multi-physics and multi-
scale framework (see, e.g. [47]) in active and soft tissues and organs in a 3D setting environment suggests the
following agenda for research:
1. Parameterised computational 3D models of the organs and tissues viewed as idealised 3D structures comple-
menting the reconstruction based approaches from imaging data;
2. Anatomically based mathematical models of processes dynamics;
3. Systemic cell recirculation in the host in conjunction with local migration within organs and tissues;
4. Biophysical properties of tissues, e.g., hydraulic conductivity, porosity;
5. Blood and lymph flow patterns in lymphoid organs;
6. Transport and distribution governing equations (e.g., sub-, normal or super-diffusion) of cytokines, chemokines,
drugs;
7. Fluid-tissue interactions;
8. Regulation of structural homeostasis in health and disease (e.g., the role of FRCs in immune responses).
As space becomes the current frontier in systems immunology [48], technologies to observe and analyze cells
and drugs distributions in tissues are developing. Implementation of a systems approach to PK-PD problems re-
quires looking at the structure, dynamics, regulation and design principles of specific organs. Whereas the dynamics
have been extensively studied within the compartmental framework, the last three topics require further investiga-
tion. This should help to overcome the concern existing in PK-PD community about the impact of mathematical
modelling and simulation [49, 50]. Linking the structure of organs to well established PK-PD modelling method-
ologies in a computationally tractable and physiologically relevant manner will require cross-disciplinary research
teams. ”This is not the end, it is not even the beginning of the end, but it is perhaps the end of the beginning.” (Sir
Winston Churchill Speech ”The End Of The Beginning”, 20th November 1942).
4.2. Drug resistance, or how to deal with the failure of targeted therapies in cancer
Targeted therapies in cancer aim at controlling known hubs in intracellular signalling pathways. The cases of
imatinib in Chronic Myelogenous Leukaemia (CML) [51] and of All-transretinoic acid in Acute Promyelocytic
Leukaemia [52] are known success stories in targeted therapies, however such cases remain rare because most
often when a hub is blocked in a cancer cell, other hubs may take over, and one such cell is enough to thrive
into an emergent drug-resistant subpopulation. The fundamental heterogeneity in phenotype of cancer cell popu-
lations [53], that has been proposed to be the result of some sort of bet hedging [54] and that can be accurately
represented in phenotype-structured models [55], may thus explain the evolution towards drug resistance in tu-
mour cell populations. To document such mechanisms, PK-PD models to describe the fate of drugs in healthy and
cancer cells are not enough. Indeed, one must consider the levels of expression of all concerned genes, as has been
recently described for instance in [56] for resistance to doxorubicin in Mutiple Myeloma. In this way, the future
prospects that are open to model such phenomena in cancer go far beyond PK-PD and offer an immense challenge
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to mathematicians: how to model and analyse the action of drugs in cancer, considering issues of both toxicity
in healthy tissues and of emergence of drug resistance in tumour cell populations? This will involve designing
relevant functional phenotypes from whole genome dynamic data processing. Some bioinformatic methods are
already available for this, but the relevant corresponding mathematical models are still to be designed, and new
and advanced statistical methods to process biological data will also be needed. When one considers the necessity
to design on the basis of such models optimal control algorithms for therapeutic strategies to be clinically efficient,
the challenge appears even more tremendous. But it has to be met.
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